These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23250612)

  • 1. [A role of alpha-7 nicotinic acetylcholine receptors in pharmacotherapy of neurodegenerative diseases].
    Makotrova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):57-9. PubMed ID: 23250612
    [No Abstract]   [Full Text] [Related]  

  • 2. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A; Albuquerque EX
    Eur J Pharmacol; 2000 Mar; 393(1-3):165-70. PubMed ID: 10771010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors.
    Bencherif M; Hauser TA; Jordan KG; Gatto GJ
    J Mol Neurosci; 2006; 30(1-2):17-8. PubMed ID: 17192609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α7 nicotinic acetylcholine receptors and their role in cognition.
    Lendvai B; Kassai F; Szájli A; Némethy Z
    Brain Res Bull; 2013 Apr; 93():86-96. PubMed ID: 23178154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
    Smulders CJ; Zwart R; Bermudez I; van Kleef RG; Groot-Kormelink PJ; Vijverberg HP
    Eur J Pharmacol; 2005 Feb; 509(2-3):97-108. PubMed ID: 15733544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive worsening of adaptive functions in Down syndrome may be mediated by the complexing of soluble Abeta peptides with the alpha 7 nicotinic acetylcholine receptor: therapeutic implications.
    Deutsch SI; Rosse RB; Mastropaolo J; Chilton M
    Clin Neuropharmacol; 2003; 26(5):277-83. PubMed ID: 14520169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.
    Wallace TL; Porter RH
    Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders.
    Mitra S; Khatri SN; Maulik M; Bult-Ito A; Schulte M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives.
    De Jaco A; Bernardini L; Rosati J; Tata AM
    Cent Nerv Syst Agents Med Chem; 2017; 17(2):100-108. PubMed ID: 27488345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.
    Vesey R; Birrell JM; Bolton C; Chipperfield RS; Blackwell AD; Dening TR; Sahakian BJ
    CNS Drugs; 2002; 16(7):485-500. PubMed ID: 12056923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
    Faghih R; Gopalakrishnan M; Briggs CA
    J Med Chem; 2008 Feb; 51(4):701-12. PubMed ID: 18198823
    [No Abstract]   [Full Text] [Related]  

  • 13. Nicotinic systems in central nervous systems disease: degenerative disorders and beyond.
    Newhouse PA; Kelton M
    Pharm Acta Helv; 2000 Mar; 74(2-3):91-101. PubMed ID: 10812945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.
    Timmermann DB; Grønlien JH; Kohlhaas KL; Nielsen EØ; Dam E; Jørgensen TD; Ahring PK; Peters D; Holst D; Christensen JK; Malysz J; Briggs CA; Gopalakrishnan M; Olsen GM
    J Pharmacol Exp Ther; 2007 Oct; 323(1):294-307. PubMed ID: 17625074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic acetylcholine receptors as therapeutic targets: emerging frontiers in basic research and clinical science--editorial perspective.
    Bertrand D; Gopalakrishnan M; Donnelly-Roberts D
    Biochem Pharmacol; 2009 Oct; 78(7):657. PubMed ID: 19576180
    [No Abstract]   [Full Text] [Related]  

  • 16. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].
    Nieoullon A
    Psychol Neuropsychiatr Vieil; 2010 Jun; 8(2):123-31. PubMed ID: 20525543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation.
    Tyagi E; Agrawal R; Nath C; Shukla R
    Neurochem Int; 2010 Jan; 56(1):135-42. PubMed ID: 19781587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats.
    Nikiforuk A; Kos T; Potasiewicz A; Popik P
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1300-13. PubMed ID: 26003081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs influencing cognitive function.
    Kuruvilla A; Devi V
    Indian J Physiol Pharmacol; 1994 Oct; 38(4):241-51. PubMed ID: 7883287
    [No Abstract]   [Full Text] [Related]  

  • 20. Nicotinic receptors and cognition in Parkinson's Disease: the importance of neuronal synchrony.
    Forgacs PB; Bodis-Wollner I
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1317-31. PubMed ID: 15480841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.